Cargando…

The majority of β-catenin mutations in colorectal cancer is homozygous

BACKGROUND: β-catenin activation plays a crucial role for tumourigenesis in the large intestine but except for Lynch syndrome (LS) associated cancers stabilizing mutations of β-catenin gene (CTNNB1) are rare in colorectal cancer (CRC). Previous animal studies provide an explanation for this observat...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnold, Alexander, Tronser, Moritz, Sers, Christine, Ahadova, Ayel, Endris, Volker, Mamlouk, Soulafa, Horst, David, Möbs, Markus, Bischoff, Philip, Kloor, Michael, Bläker, Hendrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594410/
https://www.ncbi.nlm.nih.gov/pubmed/33115416
http://dx.doi.org/10.1186/s12885-020-07537-2
_version_ 1783601628299919360
author Arnold, Alexander
Tronser, Moritz
Sers, Christine
Ahadova, Ayel
Endris, Volker
Mamlouk, Soulafa
Horst, David
Möbs, Markus
Bischoff, Philip
Kloor, Michael
Bläker, Hendrik
author_facet Arnold, Alexander
Tronser, Moritz
Sers, Christine
Ahadova, Ayel
Endris, Volker
Mamlouk, Soulafa
Horst, David
Möbs, Markus
Bischoff, Philip
Kloor, Michael
Bläker, Hendrik
author_sort Arnold, Alexander
collection PubMed
description BACKGROUND: β-catenin activation plays a crucial role for tumourigenesis in the large intestine but except for Lynch syndrome (LS) associated cancers stabilizing mutations of β-catenin gene (CTNNB1) are rare in colorectal cancer (CRC). Previous animal studies provide an explanation for this observation. They showed that CTNNB1 mutations induced transformation in the colon only when CTNNB1 was homozygously mutated or when membranous β-catenin binding was hampered by E-cadherin haploinsufficiency. We were interested, if these mechanisms are also found in human CTNNB1 mutated CRCs. RESULTS: Among 869 CRCs stabilizing CTNNB1 mutations were found in 27 cases. Homo- or hemizygous CTNNB1 mutations were detected in 74% of CTNNB1 mutated CRCs (13 microsatellite instabile (MSI-H), 7 microsatellite stabile (MSS)) but only in 3% (1/33) of extracolonic CTNNB1 mutated cancers. In contrast to MSS CRC, CTNNB1 mutations at codon 41 or 45 were highly selected in MSI-H CRC. Of the examined three CRC cell lines, β-catenin and E-cadherin expression was similar in cell lines without or with hetereozygous CTNNB1 mutations (DLD1 and HCT116), while a reduced E-cadherin expression combined with cytoplasmic accumulation of β-catenin was found in a cell line with homozygous CTNNB1 mutation (LS180). Reduced expression of E-cadherin in human MSI-H CRC tissue was identified in 60% of investigated cancers, but no association with the CTNNB1 mutational status was found. CONCLUSIONS: In conclusion, this study shows that in contrast to extracolonic cancers stabilizing CTNNB1 mutations in CRC are commonly homo- or hemizygous indicating a higher threshold of β-catenin stabilization to be required for transformation in the colon as compared to extracolonic sites. Moreover, we found different mutational hotspots in CTNNB1 for MSI-H and MSS CRCs suggesting a selection of different effects on β-catenin stabilization according to the molecular pathway of tumourigenesis. Reduced E-cadherin expression in CRC may further contribute to higher levels of transcriptionally active β-catenin, but it is not directly linked to the CTNNB1 mutational status. SUPPLEMENTARY INFORMATION: Supplementary information accompanies this paper at 10.1186/s12885-020-07537-2.
format Online
Article
Text
id pubmed-7594410
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75944102020-10-30 The majority of β-catenin mutations in colorectal cancer is homozygous Arnold, Alexander Tronser, Moritz Sers, Christine Ahadova, Ayel Endris, Volker Mamlouk, Soulafa Horst, David Möbs, Markus Bischoff, Philip Kloor, Michael Bläker, Hendrik BMC Cancer Research Article BACKGROUND: β-catenin activation plays a crucial role for tumourigenesis in the large intestine but except for Lynch syndrome (LS) associated cancers stabilizing mutations of β-catenin gene (CTNNB1) are rare in colorectal cancer (CRC). Previous animal studies provide an explanation for this observation. They showed that CTNNB1 mutations induced transformation in the colon only when CTNNB1 was homozygously mutated or when membranous β-catenin binding was hampered by E-cadherin haploinsufficiency. We were interested, if these mechanisms are also found in human CTNNB1 mutated CRCs. RESULTS: Among 869 CRCs stabilizing CTNNB1 mutations were found in 27 cases. Homo- or hemizygous CTNNB1 mutations were detected in 74% of CTNNB1 mutated CRCs (13 microsatellite instabile (MSI-H), 7 microsatellite stabile (MSS)) but only in 3% (1/33) of extracolonic CTNNB1 mutated cancers. In contrast to MSS CRC, CTNNB1 mutations at codon 41 or 45 were highly selected in MSI-H CRC. Of the examined three CRC cell lines, β-catenin and E-cadherin expression was similar in cell lines without or with hetereozygous CTNNB1 mutations (DLD1 and HCT116), while a reduced E-cadherin expression combined with cytoplasmic accumulation of β-catenin was found in a cell line with homozygous CTNNB1 mutation (LS180). Reduced expression of E-cadherin in human MSI-H CRC tissue was identified in 60% of investigated cancers, but no association with the CTNNB1 mutational status was found. CONCLUSIONS: In conclusion, this study shows that in contrast to extracolonic cancers stabilizing CTNNB1 mutations in CRC are commonly homo- or hemizygous indicating a higher threshold of β-catenin stabilization to be required for transformation in the colon as compared to extracolonic sites. Moreover, we found different mutational hotspots in CTNNB1 for MSI-H and MSS CRCs suggesting a selection of different effects on β-catenin stabilization according to the molecular pathway of tumourigenesis. Reduced E-cadherin expression in CRC may further contribute to higher levels of transcriptionally active β-catenin, but it is not directly linked to the CTNNB1 mutational status. SUPPLEMENTARY INFORMATION: Supplementary information accompanies this paper at 10.1186/s12885-020-07537-2. BioMed Central 2020-10-28 /pmc/articles/PMC7594410/ /pubmed/33115416 http://dx.doi.org/10.1186/s12885-020-07537-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Arnold, Alexander
Tronser, Moritz
Sers, Christine
Ahadova, Ayel
Endris, Volker
Mamlouk, Soulafa
Horst, David
Möbs, Markus
Bischoff, Philip
Kloor, Michael
Bläker, Hendrik
The majority of β-catenin mutations in colorectal cancer is homozygous
title The majority of β-catenin mutations in colorectal cancer is homozygous
title_full The majority of β-catenin mutations in colorectal cancer is homozygous
title_fullStr The majority of β-catenin mutations in colorectal cancer is homozygous
title_full_unstemmed The majority of β-catenin mutations in colorectal cancer is homozygous
title_short The majority of β-catenin mutations in colorectal cancer is homozygous
title_sort majority of β-catenin mutations in colorectal cancer is homozygous
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594410/
https://www.ncbi.nlm.nih.gov/pubmed/33115416
http://dx.doi.org/10.1186/s12885-020-07537-2
work_keys_str_mv AT arnoldalexander themajorityofbcateninmutationsincolorectalcancerishomozygous
AT tronsermoritz themajorityofbcateninmutationsincolorectalcancerishomozygous
AT serschristine themajorityofbcateninmutationsincolorectalcancerishomozygous
AT ahadovaayel themajorityofbcateninmutationsincolorectalcancerishomozygous
AT endrisvolker themajorityofbcateninmutationsincolorectalcancerishomozygous
AT mamlouksoulafa themajorityofbcateninmutationsincolorectalcancerishomozygous
AT horstdavid themajorityofbcateninmutationsincolorectalcancerishomozygous
AT mobsmarkus themajorityofbcateninmutationsincolorectalcancerishomozygous
AT bischoffphilip themajorityofbcateninmutationsincolorectalcancerishomozygous
AT kloormichael themajorityofbcateninmutationsincolorectalcancerishomozygous
AT blakerhendrik themajorityofbcateninmutationsincolorectalcancerishomozygous
AT arnoldalexander majorityofbcateninmutationsincolorectalcancerishomozygous
AT tronsermoritz majorityofbcateninmutationsincolorectalcancerishomozygous
AT serschristine majorityofbcateninmutationsincolorectalcancerishomozygous
AT ahadovaayel majorityofbcateninmutationsincolorectalcancerishomozygous
AT endrisvolker majorityofbcateninmutationsincolorectalcancerishomozygous
AT mamlouksoulafa majorityofbcateninmutationsincolorectalcancerishomozygous
AT horstdavid majorityofbcateninmutationsincolorectalcancerishomozygous
AT mobsmarkus majorityofbcateninmutationsincolorectalcancerishomozygous
AT bischoffphilip majorityofbcateninmutationsincolorectalcancerishomozygous
AT kloormichael majorityofbcateninmutationsincolorectalcancerishomozygous
AT blakerhendrik majorityofbcateninmutationsincolorectalcancerishomozygous